InnoCan PharmaHAM:IP40 +6.19%62 Current Ratio is 5.52 as of Mar. 2026, which is 56% above its 10-year median of 3.54. GuruFocus rates HAM:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.62 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,987 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 89.98% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. InnoCan Pharma's current ratio for the quarter that ended in Mar. 2026 was 5.52.
InnoCan Pharma has a current ratio of 5.52. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for InnoCan Pharma's Current Ratio or its related term are showing as below:
HAM:IP40'
s Current Ratio Range Over the Past 10 Years
Min: 0.54 Med: 3.54 Max: 9.41
Current: 5.52
During the past 8 years, InnoCan Pharma's highest Current Ratio was 9.41. The lowest was 0.54. And the median was 3.54.
HAM:IP40's Current Ratio is ranked better than 89.98% of 1987
companies
in the Consumer Packaged Goods industry
Industry Median: 1.73
vs HAM:IP40: 5.52
InnoCan Pharma (HAM:IP40) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
InnoCan Pharma Current Ratio Related Terms
InnoCan Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Current Ratio Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Current Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a Current Ratio of 5.52 as of Mar. 2026. This is 56% above median its historical median of 3.54. Over the past decade, InnoCan Pharma's Current Ratio has ranged from 0.54 to 9.41. According to the industry distribution chart, InnoCan Pharma ranks #199 out of 1987 companies in the Consumer Packaged Goods industry, placing it in the top 10%.
Is InnoCan Pharma's Current Ratio too high?
InnoCan Pharma's current Current Ratio of 5.52 is 56% above median its 10-year median of 3.54. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 9.41. The Consumer Packaged Goods industry median Current Ratio is 1.73. InnoCan Pharma's value of 5.52 is 219.1% above this industry median. Based on the distribution chart, InnoCan Pharma ranks #199 out of 1987 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Current Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #199 out of 1987 companies for Current Ratio. This places InnoCan Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.73. InnoCan Pharma's value of 5.52 is 219.1% above this benchmark. Historically, InnoCan Pharma's own Current Ratio has ranged from 0.54 to 9.41 over the past decade. While the company's 10-year median is 3.54 vs. the industry median of 1.73, InnoCan Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Consumer Packaged Goods company?
The median Current Ratio among Consumer Packaged Goods companies is 1.73, based on 1,987 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current Current Ratio of 5.52 is 219.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median Current Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Current Ratio is 5.52, which is 56% above median its own 10-year median of 3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.62, compared to a current price of €1.63 — trading 83.1% below its estimated fair value. The current Current Ratio is 5.52, which is 56% above median its 10-year median of 3.54 and 219.1% above the Consumer Packaged Goods industry median of 1.73. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Current Ratio is 5.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.63 is trading 83.1% below its estimated GF Value™ of €9.62.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Current Ratio: 5.52 (56% above median its 10-year median of 3.54)
GF Value™: €9.62 vs. price of €1.63 (83.1% below fair value)
Industry Position: 219.1% above the Consumer Packaged Goods median (#199 of 1987)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for HAM:IP40
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
